847775-12-6 Usage
Chemical structure
The compound contains a naphthyridine ring, a chloro substituent, and an ethyl ester group.
Pharmacological properties
The compound has potential pharmacological properties and may be used in the development of new drugs for various medical conditions.
Research status
More research is needed to fully understand the potential uses and effects of this chemical.
Molecular weight
351.78 g/mol
Appearance
The compound is likely to be a solid, based on its molecular weight and structure.
Solubility
The compound may be soluble in organic solvents such as ethanol, methanol, or dimethyl sulfoxide (DMSO), but its solubility in water is not known.
Stability
The stability of the compound under different conditions (e.g., temperature, pH, light exposure) is not known and would need to be determined through further research.
Synthesis
The compound can be synthesized through a series of chemical reactions, likely involving the formation of the naphthyridine ring, introduction of the chloro substituent, and formation of the ethyl ester group.
Biological activity
The compound may have potential biological activity, but its specific targets and mechanisms of action would need to be determined through further research.
Check Digit Verification of cas no
The CAS Registry Mumber 847775-12-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,4,7,7,7 and 5 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 847775-12:
(8*8)+(7*4)+(6*7)+(5*7)+(4*7)+(3*5)+(2*1)+(1*2)=216
216 % 10 = 6
So 847775-12-6 is a valid CAS Registry Number.
847775-12-6Relevant academic research and scientific papers
SUBSTITUTED NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF MACROPHAGE MIGRATION INHIBITORY FACTOR AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES
-
Page/Page column 116; 167-168, (2010/02/11)
Inhibitors of MIF having a naphthyridine backbone are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with MIF activity. The inhibitors of MIF have the following structures: (Ia), (Ib), (Ic), (Id) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein n, R, R1, R2, X, Y and Z are as defined herein. Compositions containing an inhibitor of MIF in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.
